Skip to main content
Hanny Al-Samkari, MD, Hematology, Boston, MA, Massachusetts General Hospital

HannyTobanAl-SamkariMD(He/Him)

Hematology • Boston, MA

Clotting Disorder, Hemophilia & Bleeding Disorder, Sickle Cell & Other Anemias

Classical Hematologist and Clinical Investigator; Co-Director, MGH Hereditary Hemorrhagic Telangiectasia Center of Excellence

Join to view full profile

Dr. Al-Samkari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Al-Samkari's full profile

Already have an account?

Summary

  • Hanny Al-Samkari, M.D. is an Associate Professor of Medicine at Harvard Medical School as well as an NIH- and U.S. DOD-funded clinical investigator and classical hematologist at the Massachusetts General Hospital (MGH) Division of Hematology Oncology. He also serves as Co-Director the MGH Hereditary Hemorrhagic Telangiectasia (HHT) Center of Excellence. His clinical and research interests are in hemostasis, thrombosis and hemolysis, with focuses in HHT, immune thrombocytopenia and other thrombocytopenias, and hereditary hemolytic anemias. He currently serves as PI for many clinical trials in these areas and is an internationally-recognized expert in the clinical development of novel therapeutics for HHT, hemolytic anemias and thrombocytopenias. He is the current Executive Editor of Hematology: The ASH Education Program, an American Society of Hematology peer-reviewed publication, and has published over 130 peer-reviewed manuscripts. His original research has been featured in The New England Journal of Medicine, The Lancet, and Blood, among other top peer-reviewed journals in hematology and medicine.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2015 - 2018
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemChief Residency, Internal Medicine, 2014 - 2015
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2011 - 2014
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 2011

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2015 - 2025
  • PA State Medical License
    PA State Medical License 2011 - 2016
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Serum Complement Levels in Immune Thrombocytopenia: Characterization and Relation to Clinical Features
    Hanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency
    Hanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Beliefs, Opinions, and Impact of Emicizumab on Hemophilia Patients: A National U.S. Survey
    Hanny Al-Samkari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bl... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Press Mentions

  • Mitapivat Superior to Placebo for Pyruvate Kinase Deficiency
    Mitapivat Superior to Placebo for Pyruvate Kinase DeficiencyApril 22nd, 2022
  • SARS-CoV-2’s Wide-Ranging Effects on the Body
    SARS-CoV-2’s Wide-Ranging Effects on the BodySeptember 1st, 2021
  • Agios Pharma (AGIO) Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at EHA
    Agios Pharma (AGIO) Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at EHAJune 11th, 2021
  • Join now to see all

Hospital Affiliations

Dr. Hanny Al-Samkari, Dr. Hanny Al-Samkari, MD, Dr. H Al-Samkari, Dr. Hanny Toban Al-Samkari